Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking

Regulations by 2FIRSTS.ai
May.17.2024
Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking
Study at GRELL 2024 reveals 80% of Brazil lung cancer deaths linked to smoking, causing concerns for public health.

According to a report from Brazilian media SBTNEWS on May 16th, a study presented at the Latin American Cancer Epidemiology and Registration Organization annual meeting (GRELL 2024) held by the Cancer Foundation in Switzerland revealed that 80% of male and female lung cancer deaths in Brazil are related to smoking (nicotine dependence). Alfredo Scaff, medical advisor at the Cancer Foundation, stated that the purpose of this study is to present data that can help prevent the disease to society.

 

A standard journalistic translation is: Skaf believes that there is a direct relationship between lung cancer and smoking habits, stating that "strictly speaking, smoking is currently the main cause of cancer worldwide, especially in Brazil.

 

There is controversy surrounding the use of e-cigarettes as a method to quit smoking, according to Scarf. In most cases, he believes it only leads to a habit of addiction to smoking. Scarf has warned that e-cigarettes may further increase the death rate from lung cancer caused by smoking. He also reminds people to be aware that nicotine is the most addictive substance in legal drugs.

 

A study has shown that the annual cost of lung cancer in Brazil reaches up to 9 billion Reais, including direct medical expenses, loss of productivity, and care for patients. However, the tobacco industry only covers 10% of the total expenses related to lung cancer in Brazil, amounting to 125 billion Reais.

 

Skaf pointed out that smoking not only leads to lung cancer but also to tooth decay, damage to the mouth and throat, chronic obstructive pulmonary disease, hypertension, acute myocardial infarction, and stroke. All of these contribute to increased direct costs in the public domain, such as treatment expenses, as well as indirect costs like productivity losses, budget expenditures, and so on.

 

The National Cancer Institute of Brazil predicts that this year there will be 14,000 new cases of lung cancer in women and 18,000 new cases in men. Additionally, the research found that the majority of patients, whether male (63.1%) or female (63.9%), seek medical attention when the disease has already reached an advanced stage. This is a widespread phenomenon across all regions of Brazil.

 

Researchers from the Cancer Foundation analyzed global data from the International Agency for Research on Cancer (IARC) and found that if current smoking patterns continue, the incidence and mortality rates of lung cancer are projected to increase by over 65% and 74% respectively by the year 2040 compared to 2022.

 

In the southern region, smoking is very common. The incidence of lung cancer in the southern region is higher, with 24.14 cases per 100,000 for men and 15.54 cases per 100,000 for women, exceeding the national average of 12.73 cases for men and 9.26 cases for women.

 

The incidence rates of lung cancer in men are lower than the national average in the southern and northeastern regions, while the incidence rates in women in the southern, northeastern, and southeastern regions are 8.27 cases, 8.46 cases, and 8.92 cases per 100,000 people, respectively, also lower than the national average. In all age groups, the male lung cancer mortality rate in the southern region is the highest in the country. According to research, the lung cancer mortality rate in men aged 40-59 in the southern region is 16.03 cases per 100,000 people, while for those aged 60 and above, it is 132.26 cases per 100,000 people.

 

According to information from the Brazilian news agency, Brazil is facing an even more serious issue as many patients are already in the late stages of their illness when seeking treatment. This is not only the case for male patients (63.1%), but also for female patients (63.9%). This is a trend seen across all regions of Brazil.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI nicotine pouch brand Nordic Spirit has entered a long-term partnership with Manchester’s Co-op Live, becoming the venue’s Official Nicotine Pouch Partner. The 23,500-capacity venue is the UK’s largest indoor live entertainment arena. Nordic Spirit will run in-venue activations for existing adult nicotine consumers and sell products at selected arena bars. The agreement was entered into before the relevant UK sponsorship restrictions were introduced, while the government intends to implement a comprehensive ban on advertising and sponsorship of vaping and nicotine products from June 1, 2027.
Sep.07